Our results together indicated that p38α deficiency-mediated sensitivity to therapeutic TKIs appeared to be common in BCR-ABL-positive CML cells and demonstrated that p38α is a promising target to lower drug dosing and increase the well-being of chronic myelogenous leukemia patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.